Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2013 Apr;57(4):1961-4. doi: 10.1128/AAC.02184-12. Epub 2013 Jan 28.

Target gene sequencing to define the susceptibility of Neisseria meningitidis to ciprofloxacin.

Author information

1
Institut Pasteur, Invasive Bacterial Infections Unit and National Reference Centre for Meningococci, Paris, France.

Abstract

Meningococcal gyrA gene sequence data, MICs, and mouse infection were used to define the ciprofloxacin breakpoint for Neisseria meningitidis. Residue T91 or D95 of GyrA was altered in all meningococcal isolates with MICs of ≥ 0.064 μg/ml but not among isolates with MICs of ≤ 0.032 μg/ml. Experimental infection of ciprofloxacin-treated mice showed slower bacterial clearance when GyrA was altered. These data suggest a MIC of ≥ 0.064 μg/ml as the ciprofloxacin breakpoint for meningococci and argue for the molecular detection of ciprofloxacin resistance.

PMID:
23357770
PMCID:
PMC3623314
DOI:
10.1128/AAC.02184-12
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center